← ANALYST RATINGS · TIPRANKS
Bicara Therapeutics Inc. (BCAX): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy2 Hold0 Sell
Ratings of 9 analysts in the last 3 months12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $32.89, the highest $45.00, the lowest $20.00. The average is +96.0% from the last price of $16.78.
Analyst ratings 14
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| David Lebowitz★★★★★★★★★★#597 · hits 60% · avg +14.2% | Citi | $35.00 | Buy | +108.6% | Reiterated | 07.10.26on TipRanks 08:35 | −0.6%next day +5.5% · 5 days +6.6% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $18.50 → $18.00−2.7% | Hold | +7.3% | Reiterated | 06.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $17.50 → $17.00−2.9% | Hold | +1.3% | Reiterated | 06.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $18.00 → $17.50−2.8% | Hold | +4.3% | Reiterated | 06.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $18.00 → $17.50−2.8% | Hold | +4.3% | Reiterated | 06.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $19.00 → $18.50−2.6% | Hold | +10.3% | Reiterated | 06.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $18.00 → $17.50−2.8% | Hold | +4.3% | Reiterated | 06.10.26on TipRanks 03:05 | — | |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $30.00 | Buy | +78.8% | Reiterated | 08.09.26on TipRanks 09:45 | +2.9%next day +0.2% · 5 days −3.3% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | $45.00 | Buy | +168.2% | Reiterated | 13.08.26on TipRanks 22:05 | +2.9%next day +3.2% · 5 days −0.2% | ↗ |
| Unknown Analyst | Wedbush | $33.00 | Buy | +96.7% | Reiterated | 12.08.26on TipRanks Aug 13 22:05 | +3.4%next day −4.8% · 5 days +5.4% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $39.00 → $37.00−5.1% | Buy | +120.5% | Reiterated | 12.08.26on TipRanks 08:20 | +3.4%next day −4.8% · 5 days +5.4% | ↗ |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $28.00 → $39.00+39.3% | Buy | +132.4% | Reiterated | 12.08.26on TipRanks 07:30 | +3.4%next day −4.8% · 5 days +5.4% | ↗ |
| Eva Fortea Verdejo★★★★★★★★★★#231 · hits 80% · avg +54.1% | Wells Fargo | $16.00 → $23.00+43.8% | Hold | +37.1% | Assigned | 12.08.26on TipRanks 06:55 | +3.4%next day −4.8% · 5 days +5.4% | ↗ |
| Richard Law CFA★★★★★★★★★★#3237 · hits 50% · avg +9.1% | Goldman Sachs | $18.00 → $20.00+11.1% | Hold | +19.2% | Assigned | 11.08.26on TipRanks Aug 12 07:15 | −14.0%next day +3.4% · 5 days +5.3% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $34.00 | Buy | +102.6% | Reiterated | 11.08.26on TipRanks Aug 12 05:25 | −14.0%next day +3.4% · 5 days +5.3% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $42.00 | Buy | +150.3% | Reiterated | 01.06.26on TipRanks 06:50 | −5.5%next day −4.9% · 5 days 0.0% | ↗ |
| Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% | Guggenheim | $42.00 | Buy | +150.3% | Reiterated | 26.05.26on TipRanks 10:50 | +0.7%next day −1.8% · 5 days −11.8% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 11.05.26on TipRanks 12:45 | +1.3%next day −2.2% · 5 days −15.8% | ↗ |
| Reni Benjamin★★★★★★★★★★#12340 · hits 34% · avg −9.2% | Citizens JMP | $31.00 | Buy | +84.7% | Initiated | 29.01.26on TipRanks 04:50 | +2.1%next day −0.4% · 5 days −8.3% | ↗ |
| Kelsey Goodwin★★★★★★★★★★#203 · hits 68% · avg +62.4% | Piper Sandler | $36.00 | Buy | +114.5% | Reiterated | 08.12.25on TipRanks 07:15 | +4.1%next day −0.8% · 5 days −2.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Bicara Therapeutics Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $32.89 at a price of $18.61 (+76.7%); now: $32.89 at $16.78 (+96.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 6 | 6 | 4 | 3 | 4 |
| Buy | 10 | 9 | 9 | 6 | 6 | 5 |
| Hold | 4 | 5 | 4 | 5 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 17.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.82 (from $-0.97 to $-0.42). Last quarter: $-0.82.
Best top-analyst consensus in the sector · General
About Bicara Therapeutics Inc.
- CEO: Claire Mazumdar Clemon
- Employees: 103
- 116 Huntington Avenue, Boston, MA, 02116, US
- www.bicara.com
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Data from the stock’s TipRanks forecast page, read 47 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗